Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multi-tumor gene signature suitable for immunooncology therapy

An oncology, tumor technology, applied in the field of multi-tumor gene signature suitable for immuno-oncology therapy, which can solve problems such as complex immune system response

Pending Publication Date: 2022-03-11
BRISTOL MYERS SQUIBB CO
View PDF212 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Immune system and response to immunotherapy have been shown to be complex

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multi-tumor gene signature suitable for immunooncology therapy
  • Multi-tumor gene signature suitable for immunooncology therapy
  • Multi-tumor gene signature suitable for immunooncology therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0254] Across multiple tumor types, inflammatory phenotypes in the tumor microenvironment (TME) are associated with improved clinical outcomes in patients treated with immuno-oncology (I-O) therapies. Infiltration of CD8+ T cells is one of the surrogate markers of inflammation and can be assessed by employing immunohistochemical (IHC) assays. However, IHC assays have a limited ability to interrogate multiple biomarkers simultaneously.

[0255] Transcriptome analysis by gene expression profiling (GEP) can be used to identify signatures that predict response to I-O therapy in cancer patients. GEP-based multiparameter tumor inflammation assays may provide a more robust characterization of inflammation by interrogating multiple genes simultaneously, extending the utility of single-gene expression analysis or protein-based IHC assessments to characterize the TME.

[0256] Purpose

[0257] The main objective of this study was to develop a GEP-based investigational use only (IUO) as...

Embodiment 2

[0272] Across multiple tumor types, an inflammatory phenotype in the tumor microenvironment (TME) is associated with improved clinical efficacy in patients treated with immuno-oncology (I-O) therapy (see Darvin P, et al Exp Mol Med 2018;50:165 ). Infiltration of CD8+ T cells can be used as a surrogate marker of inflammation and is often assessed using immunohistochemistry (IHC) (see, e.g., Barnes et al., Br J Cancer 2017; 117:451-460; and Stoll et al. Oncotarget 2015 ; 6:11894-11909). Interrogation of multiple biomarkers by IHC has its limitations. Simultaneous analysis of multiple transcripts in the TME using gene expression profiling (GEP) can provide a robust characterization of inflammation.

[0273] There are a number of GEP platforms available, including RNA sequencing (RNA-seq) and GEP panels that target selected sets of genes or pathways. However, cross-platform consistency is still to be determined.

[0274] Gene expression signatures indicative of inflammation in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides a method of identifying a subject suitable for immunooncology (I-O) therapy comprising measuring expression of one or more genes of a generic tumor inflammation genome set. In some aspects, the method further comprises administering an I-O therapy to the subject. In some aspects, the I-O therapy comprises administering to the subject an anti-PD-1 antibody, or an antigen-binding portion thereof, or an anti-PD-L1 antibody, or an antigen-binding portion thereof.

Description

[0001] Cross References to Related Applications [0002] This PCT application claims the benefit of priority to U.S. Provisional Application No. 62 / 854,885, filed May 30, 2019, and U.S. Provisional Application No. 63 / 024,989, filed May 14, 2020, each of which is incorporated by reference in its entirety This article. technical field [0003] The present disclosure provides a method for treating a subject with a tumor using immunotherapy. Background technique [0004] Human cancers have numerous genetic and epigenetic alterations that generate neoantigens that are potentially recognized by the immune system (Sjoblom et al., Science (2006) 314(5797):268-274). The adaptive immune system, composed of T and B lymphocytes, has a powerful anticancer potential, with broad capabilities and precise specificity in response to diverse tumor antigens. Furthermore, the immune system exhibits considerable plasticity and memory components. Successfully harnessing all of these properties ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574A61K39/395A61P35/00
CPCC12Q1/6886G01N33/57484C07K16/2818C07K16/2827A61P35/00C12Q2600/106C12Q2600/158G01N2800/52A61K2039/505A61K2039/507G01N33/574C07K2317/24C07K2317/76G01N33/57492
Inventor P·M·萨伯张兰K·H·德赛N·阿德亚戚振豪K·泽尔巴S·A·伊利S·潘特G·A·格林
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com